Pharming Group (NASDAQ:PHAR – Get Free Report) and Dyadic International (NASDAQ:DYAI – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.
Analyst Ratings
This is a breakdown of recent recommendations for Pharming Group and Dyadic International, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pharming Group | 2 | 0 | 3 | 0 | 2.20 |
| Dyadic International | 1 | 0 | 1 | 0 | 2.00 |
Pharming Group currently has a consensus target price of $38.67, suggesting a potential upside of 294.56%. Dyadic International has a consensus target price of $3.00, suggesting a potential upside of 560.79%. Given Dyadic International’s higher possible upside, analysts plainly believe Dyadic International is more favorable than Pharming Group.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pharming Group | $376.13 million | 1.84 | $2.85 million | $0.12 | 81.67 |
| Dyadic International | $3.09 million | 5.89 | -$7.36 million | ($0.23) | -1.97 |
Pharming Group has higher revenue and earnings than Dyadic International. Dyadic International is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Pharming Group and Dyadic International’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pharming Group | 2.51% | 3.40% | 1.90% |
| Dyadic International | -201.43% | -2,920.31% | -84.77% |
Risk & Volatility
Pharming Group has a beta of -0.05, meaning that its stock price is 105% less volatile than the S&P 500. Comparatively, Dyadic International has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.
Insider and Institutional Ownership
0.0% of Pharming Group shares are held by institutional investors. Comparatively, 27.9% of Dyadic International shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 20.9% of Dyadic International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Pharming Group beats Dyadic International on 9 of the 14 factors compared between the two stocks.
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
About Dyadic International
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
